Teri Lawver

Teri Lawver

Director/Board Member at ALTIMMUNE, INC.

Net worth: - $ as of 2026-05-30

59 year
Health Technology
Consumer Services
Commercial Services

Profile

Teri L.
Lawver
is currently Independent Director at Altimmune, Inc. since 2025, Trustee at New Jersey Symphony Orchestra, and Chief Commercial Officer & Senior Vice President at Celldex Therapeutics, Inc. starting in 2025.
Former roles include Chairman at Episcopal Relief & Development Corp.
from 2019 to 2025, Director at Episcopal Relief & Development Corp., Principal at Centocor, Inc., Vice President-Immunology at Johnson & Johnson, General Manager at Animas LLC, Derivatives Analyst at Bloomberg, Inc., Chief Commercial Officer & Executive VP at DexCom, Inc. from 2023 to 2024, and Associate Principal at McKinsey & Co., Inc. from 1994 to 2002.
Education includes undergraduate studies at Georgetown University and an MBA from The Fuqua School of Business.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-04-30 0 ( -.--% ) - $ 2026-05-30

Teri Lawver active positions

CompaniesPositionStart
ALTIMMUNE, INC. Director/Board Member 2025-02-23
CELLDEX THERAPEUTICS, INC. Corporate Officer/Principal 2025-11-09
Director/Board Member -

Former positions of Teri Lawver

CompaniesPositionEnd
Chairman 2024-12-31
DEXCOM, INC. Corporate Officer/Principal 2024-11-30
Corporate Officer/Principal 2001-12-31
Corporate Officer/Principal -
JOHNSON & JOHNSON Corporate Officer/Principal -
See the detail of Teri Lawver's experience

Training of Teri Lawver

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

99

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Technology Services

Health Technology

Consumer Services

Commercial Services

Consumer Services

Health Technology

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!